Citation

Laforgue E, Sauvaget A, Bulteau S, Vanelle JM. Ann. Med. Psychol. (Paris) 2016; 174(1): 60-63.

Copyright

(Copyright © 2016, Societe Medico-Psychologique, Publisher Elsevier Publishing)

DOI

10.1016/j.amp.2015.12.007

PMID

unavailable

Abstract

Major depressive disorder is a frequent and severe illness with significant socioeconomic impact. Classic antidepressants, based on the tri-mono-aminergic hypothesis, have limited global efficiency because of a delayed action and a moderate responding and remitting rate. Evidence of glutamatergic system involvement in mood disorder associated with the discovery of the NMDA receptor antagonist ketamine fast and robust antidepressant effect provides new therapeutic potentialities. This article reviews various uses of ketamine in depressive states. Different clinical studies find a rapid action on most depressive symptoms including suicidal thoughts with a 0.5 mg/kg ketamine infusion. This effect is reversible and transient within a week. Side effects, mainly psychomimetics, are also transient within a couple of hours. Lack of large-population studies, intravenous administration method and risk of misuse are the main restrictions to a more widespread use. However, ketamine use as "starter" with an antidepressant medication, as option in treatment-resistant depression or suicidal emergency management should be some therapeutic potential innovations. © 2015.

Language: fr

Keywords

human; Depression; ketamine; suicidal ideation; depression; Suicide risk; Ketamine; Antidepressant; psychometry; drug effect; symptom; unspecified side effect; Literature review; Article; Sismotherapy; antidepressant activity; Drug administration; Pharmaopsychology